Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

Background: A disappearance of RAS mutations in the plasma of about 50% of mCRCs (metastatic colorectal cancers) treated with bevacizumab-based chemotherapy has been reported. Our aim was to evaluate the same issue at tissue level. Materials and Methods: Using next-generation sequencing and real-tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Epistolio, Samantha, Cefalì, Marco, Spina, Paolo, Molinari, Francesca, Movilia, Alessandra, Cergnul, Massimiliano, Mazzucchelli, Luca, De Dosso, Sara, Frattini, Milo, Saletti, Piercarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169066/
https://www.ncbi.nlm.nih.gov/pubmed/34084279
http://dx.doi.org/10.18632/oncotarget.27965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169066/
https://www.ncbi.nlm.nih.gov/pubmed/34084279
http://dx.doi.org/10.18632/oncotarget.27965

Ejemplares similares